| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Stock-based compensation | -1,928 | 298 | 438 | 1,355 |
| Gain from early lease termination | NaN | 2,949 | NaN | NaN |
| Finance income, net | -385 | 10 | -19 | -247 |
| Loss (income) from change in fair value of liability-classified warrants | -14,056 | 4,429 | -730 | 2,412 |
| Day one loss upon entering transaction | 5,226 | NaN | NaN | NaN |
| Ipr&d impairment | NaN | 11,842 | NaN | NaN |
| Value of warrants issued in connection with private placement | 186 | 0 | 0 | 0 |
| Other long-lived asset impairment | NaN | 1,653 | NaN | NaN |
| Gain from deconsolidation of subsidiary | 1,860 | NaN | NaN | NaN |
| Other current assets | 1,412 | -491 | -656 | -1,096 |
| Trade accounts payable | 274 | 1,612 | -668 | 294 |
| Other accounts payable | -1,201 | -597 | -429 | -2,404 |
| Net loss | -19,140 | -13,337 | -9,166 | -13,696 |
| Depreciation | 0 | 1,153 | 1,241 | 528 |
| Revaluation of contingent consideration | 0 | -34 | -46 | 3 |
| Changes in contract liability | NaN | 0 | 0 | 0 |
| Loss from sale and disposal of fixed assets, net | 0 | -40 | 0 | -165 |
| Goodwill impairment | NaN | 0 | 0 | NaN |
| Net change in operating leases | 0 | -119 | 42 | 3 |
| Net cash used in operating activities | -5,414 | -4,386 | -7,183 | -14,821 |
| Purchase of property and equipment | NaN | 0 | 2 | 0 |
| Decrease in cash as a result of deconsolidation of subsidiary | 996 | NaN | NaN | NaN |
| Proceeds from sale of property and equipment | 0 | 1 | 0 | 109 |
| Issuance of redeemable convertible preferred shares under march 2024 pipe | NaN | 0 | 0 | 0 |
| Cash and restricted cash acquired from the apt acquisition | NaN | 0 | 0 | 0 |
| Issuance of common stock under inducement letter agreements | NaN | 0 | 0 | 6,473 |
| March 2024 pipe issuance costs | NaN | 0 | 0 | 0 |
| Net cash used in investing activities | -996 | 1 | -2 | 109 |
| Issuance cost from the apt acquisition | NaN | NaN | 0 | 0 |
| Repayment of long-term debt | NaN | 0 | 0 | 0 |
| Proceeds from issuance of preferred share and warrants under january 2026 private placement, net of issuance costs | 2,623 | 0 | 0 | 0 |
| Issuance of common stock under february 2025 spa | 0 | 0 | 0 | 996 |
| Pre-funded warrants exercise | NaN | 0 | 0 | 2 |
| February 2025 spa issuance costs | 0 | 0 | 0 | 118 |
| Issuance of common warrants under february 2025 spa | 0 | 0 | 0 | 4,531 |
| Issuance of common stock under inducement letter agreements | 0 | 1,251 | 54 | 0 |
| Net cash provided by financing activities | 2,623 | 1,251 | 54 | 11,884 |
| Increase (decrease) in cash, cash equivalents and restricted cash | -3,787 | NaN | NaN | NaN |
| Increase (decrease) in cash, cash equivalents and restricted cash | -3,787 | -3,134 | -7,131 | -2,828 |
| Effect of exchange rate changes on cash | NaN | NaN | 53 | NaN |
| Cash, cash equivalents and restricted cash at beginning of year | 8,069 | NaN | 17,975 | NaN |
| Cash, cash equivalents and restricted cash at end of year | 1,168 | NaN | 8,069 | NaN |
BiomX Inc. (PHGE)
BiomX Inc. (PHGE)